Who are CSII, Metformin, Pioglitazone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/csii-metformin-pioglitazone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CSII, Metformin, Pioglitazone — Competitive Intelligence Brief

CSII, Metformin, Pioglitazone (CSII, Metformin, Pioglitazone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin + biguanide + thiazolidinedione combination. Area: Diabetes.

marketed Insulin + biguanide + thiazolidinedione combination Insulin receptor (CSII); AMPK/mitochondrial function (metformin); PPAR-γ (pioglitazone) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

CSII, Metformin, Pioglitazone (CSII, Metformin, Pioglitazone) — Sun Yat-sen University. This is a combination therapy using continuous subcutaneous insulin infusion (CSII) with metformin and pioglitazone to improve glycemic control through multiple pathways: insulin replacement, reduced hepatic glucose production, and enhanced insulin sensitivity.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CSII, Metformin, Pioglitazone TARGET	CSII, Metformin, Pioglitazone	Sun Yat-sen University	marketed	Insulin + biguanide + thiazolidinedione combination	Insulin receptor (CSII); AMPK/mitochondrial function (metformin); PPAR-γ (pioglitazone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin + biguanide + thiazolidinedione combination class)

Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CSII, Metformin, Pioglitazone — Competitive Intelligence Brief. https://druglandscape.com/ci/csii-metformin-pioglitazone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab